Recent Posts

Post thread…


abbott diabetics - Abbott

  • anonymous said:
    Do you get micro managed here? How often to managers do ride alongs?
    Click to expand...
    DSS rep here and it’s ridiculous with mgr field travel. No different than big pharma that I left to come here. Frustrating!

anonymous
May 18, 2025 at 11:29 PM
RLT - Novartis

  • anonymous said:
    Layers upon layers. Too many silos. CE, NPS, and now this hybrid of MPA role. All have their own managers, RDs, and EDs. Novartis needs to cutback the leadership levels. Too many chiefs, not enough Indians. With 2025 expected performance being way below expectations, this is where the cuts need to happen.
    Click to expand...
    But they won’t - why do we have ED’s? Even in marketing. Waste of money

anonymous
May 18, 2025 at 11:16 PM
Pre-Employment Drug Test & THC - Vanda Pharmaceuticals

  • Can anyone shed any light regarding Vanda’s pre-employment drug test and if they permit medical marijuana cards? I know they screen for THC but I’m curious if anyone has submitted a positive-THC test and still been granted employment.

    Note: I have stopped smoking since being offered the job (sales). I am worried it won’t exit my system in time and my offer will be revoked.

    Please let me know if you know anyone who has been in my shoes, and how HR handled it. Thank you!

anonymous
May 18, 2025 at 11:15 PM
ABM Hawaii Position - Galderma

  • DON’T DO IT.

anonymous
May 18, 2025 at 10:59 PM
PrEP is Big Brother now - Gilead Sciences

  • anonymous said:
    I applaud your enthusiasm but don’t get high on your own supply. We still have to wait & see if HCPs embrace Lenacapivar.

    What we learned from Covid is, price matters. Although Remdesivir was & still is the clinically superior drug, HCPs didn’t care because it cost too much. As a result HCPs looked for ways to save on cost by using other less effective (per clinical trail) drugs.

    Lenacapivar will either be:
    1. The hit you’re predicting it to be or Lenacapivar’s price will be an opportunity for Apertude to reposition itself as the more affordable option.

    2. Or Lenacapivar’s high price tag may indirectly prompt HCPs to write more Descovy scripts as an alternative to Lenacapivar; just like Hospitals prescribed Paxlovid as cost saving alternative to Remdesivir.
    Click to expand...
    There were ways to stave off the Paxlovid use but the person placed in charge of pricing and strategy didn't know what the was doing. She was promoted by the way which isn't a shock. That's how Gilead rolls. Gilead would've sacrificed very little and the return would have paid off in spades but they were too too short sighted. Gilead politics are the worst in the industry and revenue suffers.

anonymous
May 18, 2025 at 10:49 PM
Top Bottom
Back
Post thread…